The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis.

Biomarkers that assess treatment response for patients with the autoimmune disorder, myasthenia gravis (MG) have not been evaluated to a significant extent. We hypothesized the pro-inflammatory cytokine, osteopontin, may be associated with variability of response to glucocorticoids (GCs) in patients with MG. A cohort of 250 MG patients treated with standardized protocol of GCs were recruited, and plasma osteopontin (OPN) and polymorphisms of its gene, secreted phosphoprotein 1 (SPP1) were evaluated. Mean OPN levels were higher in patients compared to healthy controls. Carriers of rs11728697*T allele (allele definition: one of two or more alternative forms of a gene) were more frequent in the poorly GC responsive group compared to the GC responsive group indicating an association of rs11728697*T allele with GC non-responsiveness. One risk haplotype (AGTACT) was identified associated with GC non-responsiveness compared with GC responsive MG group. Genetic variations of Spp1 was found associated with the response to GC among MG patients.